Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling

MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
July 19, 2023 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds

MINNEAPOLIS and LOUISVILLE, Ky., July 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
July 17, 2023 06:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
July 10, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 28, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 26, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes

MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
June 21, 2023 16:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Closing of Approximately $8.5 Million Public Offering

MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 16, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Pricing of Approximately $8.5 Million Public Offering

MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 13, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
June 01, 2023 08:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes

MINNEAPOLIS, June 01, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...